ES2943063T5 - Multispecific anti-tcr delta variable 1 antibodies - Google Patents

Multispecific anti-tcr delta variable 1 antibodies

Info

Publication number
ES2943063T5
ES2943063T5 ES21756070T ES21756070T ES2943063T5 ES 2943063 T5 ES2943063 T5 ES 2943063T5 ES 21756070 T ES21756070 T ES 21756070T ES 21756070 T ES21756070 T ES 21756070T ES 2943063 T5 ES2943063 T5 ES 2943063T5
Authority
ES
Spain
Prior art keywords
seq
antibody
sequence
cells
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21756070T
Other languages
English (en)
Spanish (es)
Other versions
ES2943063T3 (es
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GammaDelta Therapeutics Ltd
Original Assignee
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2943063(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed by GammaDelta Therapeutics Ltd filed Critical GammaDelta Therapeutics Ltd
Publication of ES2943063T3 publication Critical patent/ES2943063T3/es
Application granted granted Critical
Publication of ES2943063T5 publication Critical patent/ES2943063T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
ES21756070T 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies Active ES2943063T5 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (2)

Publication Number Publication Date
ES2943063T3 ES2943063T3 (es) 2023-06-08
ES2943063T5 true ES2943063T5 (en) 2026-05-05

Family

ID=80247426

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21756070T Active ES2943063T5 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies
ES23187269T Active ES2993071T3 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES23187269T Active ES2993071T3 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Country Status (18)

Country Link
EP (7) EP4218932A3 (cg-RX-API-DMAC7.html)
JP (1) JP7847579B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083267A (cg-RX-API-DMAC7.html)
CN (1) CN116209456A (cg-RX-API-DMAC7.html)
AU (1) AU2021323512A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002741A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188682A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023003009A2 (cg-RX-API-DMAC7.html)
DK (2) DK4269444T5 (cg-RX-API-DMAC7.html)
ES (2) ES2943063T5 (cg-RX-API-DMAC7.html)
FI (2) FI4010082T4 (cg-RX-API-DMAC7.html)
IL (1) IL300517A (cg-RX-API-DMAC7.html)
LT (2) LT4269444T (cg-RX-API-DMAC7.html)
MX (1) MX2023001728A (cg-RX-API-DMAC7.html)
PL (2) PL4269444T3 (cg-RX-API-DMAC7.html)
PT (2) PT4269444T (cg-RX-API-DMAC7.html)
SI (2) SI4010082T2 (cg-RX-API-DMAC7.html)
WO (1) WO2022034562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
EP4544302A1 (en) * 2022-06-23 2025-04-30 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2026026858A1 (en) * 2024-07-30 2026-02-05 Biomap (Suzhou) Intelligent Technology Limited Dsg2 antibody and uses thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
US20260152558A1 (en) * 2024-11-27 2026-06-04 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
WO2026152120A2 (en) 2025-01-13 2026-07-16 HCW Biologics, Inc. Chimeric polypeptides and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3490675A4 (en) 2016-07-29 2020-07-29 New York University T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
WO2019005637A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3127103A1 (en) * 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2020159368A1 (en) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
CA3148588A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체

Also Published As

Publication number Publication date
EP4010082A1 (en) 2022-06-15
LT4269444T (lt) 2024-09-25
EP4010082B2 (en) 2025-12-31
EP4269446A2 (en) 2023-11-01
EP4265642A3 (en) 2024-02-14
ES2993071T3 (en) 2024-12-20
KR20230083267A (ko) 2023-06-09
WO2022034562A1 (en) 2022-02-17
EP4269444A2 (en) 2023-11-01
PT4269444T (pt) 2024-09-05
EP4269445B1 (en) 2024-06-26
FI4269444T3 (fi) 2024-09-20
EP4218932A2 (en) 2023-08-02
EP4265643A2 (en) 2023-10-25
EP4265643A3 (en) 2024-02-14
EP4269446A3 (en) 2024-02-14
FI4010082T3 (fi) 2023-04-04
IL300517A (en) 2023-04-01
JP2023537534A (ja) 2023-09-01
LT4010082T (lt) 2023-03-10
DK4010082T4 (en) 2026-02-16
EP4010082B9 (en) 2026-03-04
SI4010082T1 (sl) 2023-04-28
DK4010082T5 (da) 2024-08-05
AU2021323512A1 (en) 2023-04-13
PL4010082T3 (pl) 2023-05-29
EP4265643B1 (en) 2024-06-26
MX2023001728A (es) 2023-04-20
PL4010082T5 (pl) 2026-03-09
EP4010082B1 (en) 2023-01-25
EP4218932A3 (en) 2023-09-27
SI4010082T2 (sl) 2026-05-29
SI4269444T1 (sl) 2024-10-30
JP7847579B2 (ja) 2026-04-17
CO2023003009A2 (es) 2023-03-17
EP4265642B1 (en) 2024-06-26
EP4269445A2 (en) 2023-11-01
CN116209456A (zh) 2023-06-02
FI4010082T4 (fi) 2026-03-24
DK4269444T5 (da) 2024-08-26
EP4265642A2 (en) 2023-10-25
PL4269444T3 (pl) 2025-01-13
ES2943063T3 (es) 2023-06-08
DK4269444T3 (en) 2024-08-19
DK4010082T3 (da) 2023-04-03
EP4269444A3 (en) 2024-02-14
CA3188682A1 (en) 2022-02-17
PT4010082T (pt) 2023-04-26
EP4269445A3 (en) 2024-02-14
BR112023002741A2 (pt) 2023-10-10
EP4269446B1 (en) 2024-06-26
EP4269444B1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
DK4269444T3 (en) Multispecific anti-tcr delta variable 1 antibodies
ZA202308120B (en) Multispecific anti-tcr delta variable 1 antibodies
IL308741A (en) Anti-SIRP-alpha antibodies
PT4214240T (pt) Anticorpos anti-ccr8
GB202105110D0 (en) Anti-CD73 antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
GB202111685D0 (en) Anti-tcr delta variable 1 antibodies
GB202102222D0 (en) Multispecific anti-TCR delta variable 1 antibodies
GB202010652D0 (en) Anti-tau antibodies
GB202008022D0 (en) Antibodies
HK40104958A (en) Multispecific anti-tcr delta variable 1 antibodies
GB202203226D0 (en) Trays
IL307332A (en) New multispecific antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202102227D0 (en) Antibodies
GB202102224D0 (en) Anti-TRC delta variable 1 antibodies
HK40105359A (en) Anti-tcr delta variable 1 antibodies
HK40076337A (en) Novel anti-tcr delta variable 1 antibodies
HK40072486A (en) Therapeutic uses of anti-tcr delta variable 1 antibodies
HK40110498A (en) Anti-polyubiquitin multispecific antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies